BioStock: Curasight announces brain cancer as initial target for uTREAT

Brain cancer will be the first indication for Curasight’s uTREAT therapy. The company’s decision to choose aggressive brain cancer for a fast single indications trial is backed by promising preclinical and clinical results demonstrating the potential of its uPAR-targeted technologies in neuro-oncology. Curasight aims to begin dosing the first patient in a clinical trial by the end of the second quarter of 2025. BioStock contacted CEO Ulrich Krasilnikoff to learn more. 

Read the full article at biostock.se:

https://www.biostock.se/en/2024/11/curasight-announces-brain-cancer-as-initial-target-for-utreat/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se